Study questions need for extra lymph node removal in certain breast cancers

NCT ID NCT07546695

Recruiting now Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews medical records of 600 people with HER2+ or triple-negative breast cancer who had chemotherapy and still had cancer in their lymph nodes. The goal is to see if skipping additional lymph node removal (axillary dissection) leads to more cancer coming back in the armpit. By analyzing past data, researchers hope to find out when this extra surgery is truly needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors decide when it is safe to skip additional lymph node surgery after chemotherapy for certain breast cancers, reducing side effects.
What could go wrong: This is a retrospective study that looks back at past medical records, not a controlled experiment. Results may not apply to all patients, and the findings are observational, not definitive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Department Breast, Abdomen, Pelvis; Universitätsspital Basel
RECRUITING

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.